BARX2

Across TCGA pan-cancer cohorts, BARX2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BARX2 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BARX2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BARX2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC are the cancer types where BARX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.943	0.547	.025	8	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

BARX2–HNSC (DFS)

Open the HNSC breakdown →